FRECUENCIA DE DISLIPIDEMIA EN PACIENTES CON 

LUPUS ERITEMATOSO SISTÉMICO

REFERENCIAS BIBLIOGRÁFICAS

1. Bruce I, et al. Natural history of hypercholesterolernia in systemic lupus ery­ thernatosus. J Rheumatol 1999; 26: 2137-43.

2. Friedrich C, et al. Managernent of lipid disorders in rheurnatologic diseases. Rheum Dis Clin N Am 1999; 25: 1152-64.

3. Ettinger, et al. Dyslipoproteinemia in systernic lupus erythematosus: Effect of corticosteroids.Am j Med 1987; 83:503-8.

4. Homcy C, et al Isquemic heart disease in systernic lupus erythematosus in the young patient: Report of six cases. Am J Cardiol 1982; 49:478-84.

5. Petri M, etal. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1993; 93:513-9.

6. ScottM, etal. Cholesterol management in the era of managed care. Am J Cardiol 1985; 53: 3 A-9A.

7. Ginzler E. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheurnatol. 1998; 12:495-5 10.

8. Manzi S. Age specific incidence rates of myocardial infárction and angina in women with systemic lupus erythernatosus; comparison with the Framingham study. Am J Epidemiol 1997; 145: 408- 15.

9. Petri M. Coronary artery disease risk factors in thejohris Hoplkins Lupi co­hort prevalence, recognition by patients and preventative practices. Med¡cine (Baltimore) 1992;71: 291-302.

10. HaiderV, etal. Coronary arterial disease in systemic lupus erythematosus: Quali­fication of degrees of narrowing in 22 necropsy patients (21 wornen) aged 16­37 years. Am J Med 1981; 70: 775-81.

11. Hodis H, et al. The lipid, lipoprotein, and apolipoprotein effects of hydroxychioroquinein patients with systemic lupus erythernatosus J Rheumatol 1993; 20:661 -5.

12. Petri M, et al. Effect of precinisone and hydroxychioroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analy­sis. Am J Med 1994;96:254-9.

13. Spiera H, et al.Myocardial infarction in four young patients with systernic lupus erythematosus. J Rheumatol 1993; 10:464-6.

14. Ward M. Premature morbidity from cardiovascular and cerebrovascular, diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42: 338-46.

15. Helve T. Prevalence and mortality rates of systernic lupus erythematosus and causes of death in SLE patients in Finiand. Scand J Rheumatol 1985; 14: 43-6.

16. Abu-Shakra M, et al. Mortality studies in systemic lupus erythernatosus: results from a single center. 1. Causes of death. J Rheumatol 1995; 22: 1259-64.

17. Ward M.Causes of death in systemic lupus erythematosus:long-term followup of an inception cohort. Arthritis Rheum 1995; 38: 1492-9.

18. Badui E, et al. Cardiovascular manifestations in systemic lupus erythernatosus: prospective study of 100 patients. Angiology 1985; 36: 431-41.

19. Galve E, et al. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988; 319:817-23.

20. Straaton K, et al. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988; 85:645-50.

21. Roldan C, et al. An echocardiographic study of valvular heart disease associ­ated with systernic lupus erythematosus. N Engl J Med 1996; 335: 1424-30.

22. Cujec B,et al.Cardiac abnormalities in patients with systernic lupus erytherna­tosus. Can J Cardiol 1991; 7: 343-9.

23. Scott M, et al. The role of cholesterol management in coronary disease risk reduction in elderly patients. Endocrinol Metabol Clin 1998; 27: 655-75.

24. Denke M, et al Hypercholesterolemia in the elderly: Resolving the treatment dilemma. Ann Interin Med 1990; 112:780-5.

25. Schectman G,etal. Dose-response characteristics of choesterol lowering grud therapies: implications for treatment. Ann Intern Med 1996; 125: 990- 1000.

26. Wallace D. Cholesterol lowering effects of hydroxychloroquine in patients with rheumatic disease: reversal of deletereous effects of corticosteoids on lipids. Am J Med 1990; 89: 322-6.

Regresar